Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson(Erasmus Hospital), Winette T.A. van der Graaf(The Netherlands Cancer Institute), Pancras C.W. Hogendoorn(Vrije Universiteit Brussel), Patrick Schöffski(KU Leuven), Angelo Paolo Dei Tos(University of Padua), Hans Gelderblom(Leiden University Medical Center), Jean‐Yves Blay(Université Claude Bernard Lyon 1), J. Martijn Kerst(The Netherlands Cancer Institute), Peter Hohenberger(University of Mannheim), Jeremy Whelan(University College London Hospitals NHS Foundation Trust), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Thierry Alcindor(McGill University), Cyril Fisher(Royal Marsden Hospital), Saskia Litière(European Organisation for Research and Treatment of Cancer), Jaap Verweij(Deutz (Germany)), Jörg T. Hartmann(University of Tübingen), Josef Sufliarsky(National Institute of Cardiovascular Diseases), C. Hermans(European Organisation for Research and Treatment of Cancer), Anders Krarup‐Hansen(Herlev Hospital)
Cited by 1,171
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k